Keywords: ADA; anti-drug antibody; nADA; neutralizing anti-drug antibody; PASI; Psoriasis Area and Severity Index; PK; pharmacokinetics; Q2W; every 2 weeks; Q4W; every 4 weeks; TE-ADA; treatment-emergent anti-drug antibody;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Disease Activity; Self-monitoring; Golimumab; PURSUIT; CCR; continuous clinical response; CRP; C-reactive protein; IBD; inflammatory bowel disease; IBDQ; inflammatory bowel disease questionnaire; PGA; physician global assessment; PROMIS; Patient Reported
Keywords: aBMD; areal bone mineral density; app; apparent; BMD; bone mineral density; BV/TV; bone volume fraction; Ct.Th; cortical thickness; DXA; dual-energy X-ray absorptiometry; FE; finite element; HR-QCT; high-resolution quantitative computed tomography; Q2W; o
Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma
Keywords: Asthma; Biologic; Eosinophil; Exacerbation; Interleukin-5 receptor; CI; confidence interval; FEV1; forced expiratory volume in 1 s; ICS; inhaled corticosteroid; IL-5; interleukin-5; LABA; long-acting β2-agonist; OCS; oral corticosteroid; Q4W; every 4 we
The efficacy advantage of evolocumab (AMG 145) dosed at 140Â mg every 2Â weeks versus 420Â mg every 4Â weeks in patients with hypercholesterolemia: Evidence from a meta-analysis
Keywords: ApoB/ApoA-I; Apolipoprotein B/Apolipoprotein A-I; ALT; Alanine aminotransferase; AST; Aspartate aminotransferase; CI; Confidence interval; CVD; Cardiovascular disease; CHD; Coronary heart disease; AMG 145; Evolocumab; Q2W; Every 2Â weeks; Q4W; Every 4Â we
PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges
Keywords: PCSK9 inhibitors; Statins; Lipid lowering therapies; LDL-C; Low-density lipoprotein cholesterol; LDL-R; Low-density lipoprotein receptor; PCSK9; Proprotein Convertase Subtilisin/Kexin type 9; ACS; Acute coronary syndrome; FDA; Food and Drug Administration
Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE
Keywords: DTR; dosing table revision; ICS; inhaled corticosteroids; KDapp; apparent equilibrium binding constant; PK-PD; pharmacokinetic and pharmacodynamic; q2w; every 2Â weeks; q4w; every 4Â weeks; sc; subcutaneous; Allergic asthma; Anti-immunoglobulin E; Dosin
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145): A Pooled Analysis of More Than 1,300 Patients in 4 Phase II Trials
Keywords: dyslipidemia; evolocumab; lipoprotein(a); PCSK9Â inhibition; CVD; cardiovascular disease; LDL; low-density lipoprotein; PCSK9; proprotein convertase subtilisin/kexin type 9; Q2W; every 2 weeks; Q4W; every 4 weeks; SC; subcutaneous; UC LDL-C; low-density l
Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial
Keywords: denosumab; osteoclasts; prostatic neoplasms; RANK ligand; urinary N-telopeptide of type I collagen, humanAE, adverse event; BCE, bone collagen equivalents; BP, bisphosphonates; Cr, creatinine; ECOG, Eastern Cooperative Oncology Group; IV, intravenous; Q4W
Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II Trial
Keywords: denosumab; osteoclasts; prostatic neoplasms; RANK ligand; urinary N-telopeptide of type I collagen; humanAE, adverse event; BCE, bone collagen equivalents; BP, bisphosphonates; Cr, creatinine; ECOG, Eastern Cooperative Oncology Group; IV, intravenous; Q4W